• Rutter, Harry
• Schomerus, Georg
• Berzigotti, Annalisa
• Guha, Neil
• Carrieri, Patrizia
• Manns, Michael P.
• Burra, Patrizia
• Karlsen, Tom H.
• Buti, Maria
• Gines, Pere
• Voigt, Kristin
• Hutchinson, Sharon
• Engebretsen, Eivind
• Zelber-Sagi, Shira
• Kleinert, Sabine
• Krag, Aleksander

Abstract

In December, 2021, the first report from the Lancet Commission on liver disease in Europe, a joint project with the European Association for the Study of the Liver (EASL), was published. 1 The Commission explored the harm to liver health in Europe that results from a combination of increasing obesity, the highest level of alcohol consumption in the world, and delays in viral hepatitis elimination. The Commission emphasised the importance of structural factors that drive risk behaviours and poor outcomes in liver disease, with disproportionate effects on disadvantaged and vulnerable populations. Such structural drivers include the heterogeneous landscape of alcohol policy in Europe, fragmented access to testing and therapy for viral hepatitis, and stigmatisation faced by individuals at risk of liver disease at the societal level and within health-care settings. 2 ,3 This stigma contributes to care avoidance and delayed diagnosis, ultimately leading to a bias in clinical pathways that prioritise managing advanced liver disease rather than early diagnosis and primary and secondary prevention of liver disease. The Commission report included ten recommendations to facilitate a shift towards health promotion, prevention, proactive case-finding, early identification of progressive liver fibrosis, and early management and treatment of liver diseases (figure). 1 The key message of the Commission was paraphrased by Ursula von der Leyen, the President of the European Commission, in her remarks made at the launch event: “in most cases, liver disease can be prevented. Prevention is the best cure that we have.”

Topics

• impedance spectroscopy
• alcohol